EligibleTrials

miR-342-5p/AnkG Pathway in Early AD Synaptic Dysfunction

Recruiting · NCT07353502 · Interventional (participants receive a specific treatment) · Lead sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine

View the official record on ClinicalTrials.gov →
Alzheimer's disease

Interventions studied

Collect peripheral blood, and if the patient consents, also collect cerebrospinal fluid.

What this trial is about

Alzheimer's disease is the most common memory loss disease among the elderly. This disease affects the patient's memory, language, attention, and behavioral abilities. Current research has found that in the early stages of the disease, synaptic connections between brain nerve cells become abnormal, but the specific cause is still unclear. Investigators' previous research discovered that in the brains of diseased mice, certain special substances (the miR 342 5p/AnkG-mediated pathway) might be related to this abnormality, and these substances can be detected in both blood and cerebrospinal fluid. Therefore, investigators want to further explore the specific mechanisms of abnormal nerve cell connections, seek biomarkers for early detection of the disease, and provide new ideas for early diagnosis in the future.

Who can take part

Age range
50 Years and older
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

1 location listed.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.